Mounjaro Side Effects: Nausea, Sulfur Burps & Timeline (2026)

01

The most common Mounjaro side effects

In placebo-controlled trials in adults with type 2 diabetes, gastrointestinal reactions were the most frequently reported Mounjaro side effects, and they were clearly dose-related. Per the FDA-approved Mounjaro label, overall GI reactions rose with dose: placebo 20.4%, Mounjaro 5 mg 37.1%, 10 mg 39.6%, 15 mg 43.6%.

The label reports the following incidence (adverse reactions in ≥5% of patients, by dose vs placebo):

(Source: FDA/Eli Lilly Mounjaro prescribing information. Mounjaro also has 2.5, 7.5, and 12.5 mg strengths used in the titration schedule; individual experience varies.)

Crucially, the label notes that most reports of nausea, vomiting, and diarrhea occurred during dose escalation and decreased over time.

GI side effects led more people to stop treatment at higher doses (3.0% at 5 mg, 5.4% at 10 mg, 6.6% at 15 mg vs 0.4% on placebo).

Mounjaro nausea

Nausea is one of the most common Mounjaro side effects, though notably it was reported by a smaller share of people (12–18%) than with some semaglutide products.

It typically peaks in the first one to three days after a dose or a dose increase, then settles as your body adjusts.

Practical strategies widely recommended by clinics such as Cleveland Clinic and Mayo Clinic: eat smaller, more frequent meals, eat slowly and stop at the first feeling of fullness, favor bland, low-fat foods, and sip fluids between meals rather than with them.

Greasy, fried, and very sweet foods tend to make Mounjaro nausea worse.

Diarrhea, vomiting, and constipation

Diarrhea is actually the GI symptom most people notice, and both diarrhea and vomiting can cause a real problem: dehydration. Because Mounjaro also blunts thirst and appetite, it is easy to under-drink.

Persistent vomiting or diarrhea that keeps you from holding down fluids is a reason to call your clinician — in rare cases severe dehydration can trigger acute kidney injury. Constipation, at the other extreme, stems from the same slowed gut motility; more fiber, adequate fluids, and regular movement usually help, but constipation with severe cramping, bloating, and vomiting can signal a bowel obstruction and should be evaluated.

Decreased appetite and other common effects

Decreased appetite is expected (it is part of how the drug works) but it rose sharply with dose (5% → 11%), so eating enough protein and staying hydrated matters.

People also report belching/burping, indigestion, injection-site reactions (redness or itching), fatigue, and dizziness. Hair thinning is sometimes reported, but with tirzepatide it is generally attributed to rapid weight change rather than a direct drug effect, and it is usually temporary.

02

Mounjaro sulfur burps ("egg burps")

One complaint people report far more with tirzepatide than with older drugs is sulfur burps — belches that smell like rotten eggs.

These are not a separately listed frequency on the FDA label, but they are a commonly discussed real-world Mounjaro side effect.

The likely mechanism: because Mounjaro slows gastric emptying, food (especially high-protein and sulfur-rich foods) sits longer in the stomach and ferments, and gut bacteria produce hydrogen sulfide gas — the source of the rotten-egg smell.

Widely suggested ways to reduce sulfur burps: eat smaller, lower-fat meals, slow down, cut back on the biggest sulfur-heavy triggers (red meat, eggs, garlic, onions, broccoli and other cruciferous vegetables, and sugary/fizzy drinks), and stay hydrated.

For most people, sulfur burps ease as the body adjusts. If they come with severe pain, persistent vomiting, or diarrhea, treat that as a red flag (see below) rather than "just burps."

03

How long do Mounjaro side effects last?

For most people, the common gastrointestinal side effects are temporary. Nausea, diarrhea, and related symptoms most often ease within a few weeks of starting Mounjaro or of each dose increase, as the body adjusts — the label itself notes GI reactions cluster during dose escalation and decrease over time.

Because side effects cluster around dose changes, a slow, gradual dose escalation is the single most effective way to limit them, which is why the manufacturer builds in a stepwise titration that begins at a low 2.5 mg starter dose that is not intended for glucose control.

If a side effect is still severe after several weeks, or you are losing weight faster than intended, that is a signal to talk with your prescriber.

They may hold your dose at its current step longer or reduce it. Do not adjust your own dose without medical guidance.

04

Dose-dependence and titration: why the ramp-up matters

Mounjaro side effects are strongly dose-dependent — the label's own numbers show more nausea, vomiting, and decreased appetite at 15 mg than at 5 mg, and more discontinuations too.

This is the reason the prescribing information uses a stepwise titration (starting at 2.5 mg) rather than starting at a full dose.

The most reliable predictor of how you will tolerate Mounjaro is how quickly the dose is increased, not any personal "toughness." If a step is hard, prescribers can slow the ramp — a decision for your clinician, not a self-adjustment.

05

Serious Mounjaro side effects and warnings

These are less common but important, and they are why Mounjaro is prescription-only and medically supervised.

Pancreatitis

The Mounjaro label warns that acute pancreatitis — including fatal and hemorrhagic or necrotizing cases — has been observed with GLP-1-based drugs.

The classic sign is severe, persistent abdominal pain, often in the upper abdomen and sometimes radiating to the back, with or without vomiting.

If this happens, stop the medicine and seek care promptly; if pancreatitis is confirmed, Mounjaro should not be restarted.

Gallbladder problems and gallstones

The label warns of acute gallbladder disease, including gallstones (cholelithiasis) and inflammation, some cases requiring gallbladder removal.

Warning signs include pain in the upper-right abdomen, fever, yellowing of the skin or eyes (jaundice), and clay-colored stools.

Delayed gastric emptying, gastroparesis, and aspiration risk

Mounjaro slows stomach emptying by design. It is not recommended in patients with severe gastrointestinal disease, including severe gastroparesis, because it has not been studied there.

There are also rare postmarketing reports of pulmonary aspiration during general anesthesia or deep sedation in people on GLP-1-based drugs who had food still in the stomach despite fasting.

Tell your care team you take Mounjaro before any surgery or procedure with sedation.

Boxed warning: thyroid C-cell tumors

Tirzepatide carries the FDA's strongest boxed warning for thyroid C-cell tumors, based on findings in rats; whether this applies to humans is not known. Mounjaro is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a lump in the neck, trouble swallowing, shortness of breath, or persistent hoarseness.

Hypoglycemia, kidney injury, retinopathy, allergic reactions

On its own Mounjaro carries a low hypoglycemia risk, but the risk rises sharply with insulin or a sulfonylurea — your clinician may lower those.

Severe vomiting or diarrhea can lead to dehydration and acute kidney injury. Because Mounjaro is used in type 2 diabetes, the label also flags possible diabetic retinopathy complications (keep recommended eye monitoring).

Serious hypersensitivity reactions (including anaphylaxis and angioedema) have also been reported.

06

When to seek care: Mounjaro red-flag table

When in doubt, call your clinician or emergency services — this table is a guide, not a substitute for professional judgment.

07

Mounjaro vs Zepbound side effects: the same molecule, different use

Mounjaro and Zepbound are both tirzepatide, so they share the same side-effect profile. The differences are in approved use (and, at the top, dose):

Because they are the same molecule, the side-effect landscape is essentially identical.

How does Mounjaro compare with Ozempic (semaglutide)? Both are injectable GLP-1-based drugs with the same broad GI profile and the same thyroid boxed warning, but Mounjaro is a dual GIP/GLP-1 agonist while Ozempic acts on GLP-1 alone.

For that comparison, see our Ozempic side effects guide.

08

Practical ways to reduce Mounjaro side effects

1. Go slow. Follow the titration schedule; never rush to a higher dose on your own.
2. Eat smaller, more frequent, lower-fat meals and stop at the first sign of fullness.
3. Hydrate — sip water through the day, especially with any vomiting or diarrhea.
4. Limit greasy, fried, very sweet, and sulfur-heavy foods (red meat, eggs, garlic, cruciferous veg) that worsen nausea and sulfur burps.
5. Add fiber and move your body to counter constipation.
6. Prioritize protein and gradual weight loss to protect muscle.
7. Track your symptoms, doses, and meals so patterns are visible for your next visit.
8. Report red-flag symptoms immediately — don't "wait it out."

Because Mounjaro side effects cluster around specific days and doses, a simple daily log of what you feel, when you dosed, and what you ate makes conversations with your clinician far more useful.

This is exactly what the Havit app is built to make effortless — log your dose, meals, and how you feel, and see your own patterns over time. (It's a tracking companion, not a medical device — always defer to your clinician.) You can also use our Mounjaro tracker.

09

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

Roughly 20–40% of the weight lost on GLP-1 therapy can come from lean (muscle) tissue rather than fat (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

The most common Mounjaro side effects

Related articles